Earnings Call · Q4 FY2025·2026-03-19

Q4 25EPS +5.56%·Rev n/aQ3 25EPS -75.00%·Rev n/aQ2 25EPS -100.00%*·Rev n/aQ1 25EPS -100.00%*·Rev n/a⚠ consensus missing

Eton Pharmaceuticals, Inc. ETON

David Krempa

Sean E. Brynjelsen — Chief Executive Officer

James R. Gruber — Chief Financial Officer

+9.2%1d on move date+9.4% vs SPY3d+25.2%5d+25.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ETON calls or request research access.

More ETON calls Browse calls Request research access